Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNG | P07510 | 1/20 | 0.30 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | CHRND | Q07001 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18477098 | 1.00 | CHRNA1 (0.30) | CHRNA1CHRNGITGA5CHRNB1CHRNB2 | |
| SCHEMBL25761222 | 0.84 | — | — | |
| SCHEMBL20465451 | 0.81 | — | — | |
| SCHEMBL18452947 | 0.81 | — | — | |
| SCHEMBL18477097 | 0.79 | — | — | |
| SCHEMBL18476689 | 0.73 | — | — | |
| SCHEMBL22354586 | 0.72 | NPSR1 (0.32) | — | |
| SCHEMBL18477092 | 0.66 | — | — | |
| SCHEMBL7599702 | 0.62 | TSHR (0.33) | — | |
| SCHEMBL9146280 | 0.61 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760723-B2 | Method of preparing a DON prodrug from L-pyroglutamic acid | DRACEN PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220194898-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2022-06-23 | — | — | US | disclosed |
| WO-2020167829-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | DRACEN PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760723-B2 | Method of preparing a DON prodrug from L-pyroglutamic acid | GLS, GLS2, GLO1 | CHRNA1 4721/4885CHRNG 4069/4885ITGA5 3994/4885 |
| US-20220194898-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | GLS, GLS2, GLO1 | CHRNA1 4721/4885CHRNG 4069/4885ITGA5 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.